Hikal Q1 FY27 Revenue at ₹403 Cr, EBITDA Margins Expand 260 bps YoY
Hikal Limited reported Q1 FY27 revenue of ₹403 crore, up 6.2% YoY. EBITDA grew 47.4% to ₹37 crore with margins expanding 260 bps to 9.2%. Pharmaceuticals revenue rose 15.2% to ₹233 crore. The company expects stepwise recovery in revenues and profitability in FY27.
The results show year-on-year growth and margin improvement, which is positive for the company's financial health. However, the commentary suggests a slower start to the fiscal year and ongoing challenges in certain segments, indicating a moderate impact.
The company reported revenue growth and significant expansion in EBITDA margins year-on-year, along with positive commentary on future recovery and business momentum.
Hikal Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting consolidated revenue of ₹403 crore, a 6.2% growth year-on-year despite geopolitical and macroeconomic headwinds. The company achieved an EBITDA margin of 9.2%, an expansion of 260 basis points year-on-year, with EBITDA at ₹37 crore, a 47.4% increase YoY.
The Pharmaceuticals business showed continued recovery, contributing 58% to the revenue with ₹233 crore, a 15.2% YoY growth. This was supported by improving customer offtake, portfolio expansion in differentiated APIs and specialty therapies, and strengthening demand in regulated and emerging markets. The company commissioned a new cGMP pilot plant in Pune and expects its DMF filing trajectory to increase. The Crop Protection business delivered revenue of ₹170 crore, impacted by customer inventory adjustments and higher input costs for CDMO, though Own Products saw sequential growth driven by domestic volumes.
Executive Chairman Jai Hiremath commented that Q1 FY27 was a slower start due to transition from regulatory-led disruption to growth. The Pharmaceutical business is in the penultimate stage of its remediation plan with the US FDA, involving significant investment to ensure compliance. He expressed confidence in capitalizing on the CDMO pipeline and specialty APIs, with continued investments in High Potency capabilities and accelerated DMF filings to strengthen the long-term competitive position.
The Crop Protection business expects sequential improvement, while the Animal Health business continued to deliver resilient performance. The Personal Care business achieved a milestone with the commissioning of the dedicated Panoli manufacturing facility. Hikal also received a Gold rating from EcoVadis, placing it in the top 5% of companies globally. The company anticipates a stepwise recovery of revenues and profitability during FY27.
What to do with a filing like this
Hikal Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.